Regan Lauer - Immunitybio Chief Officer
| IBRX Stock | USD 3.90 0.55 16.42% |
Executive
Regan Lauer is Chief Officer of Immunitybio
| Age | 55 |
| Address | 3530 John Hopkins Court, San Diego, CA, United States, 92121 |
| Phone | 844 696 5235 |
| Web | https://immunitybio.com |
Regan Lauer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Regan Lauer against Immunitybio stock is an integral part of due diligence when investing in Immunitybio. Regan Lauer insider activity provides valuable insight into whether Immunitybio is net buyers or sellers over its current business cycle. Note, Immunitybio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Immunitybio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Regan Lauer over two months ago Disposition of 21031 shares by Regan Lauer of Immunitybio subject to Rule 16b-3 |
Immunitybio Management Efficiency
The company has return on total asset (ROA) of (0.5635) % which means that it has lost $0.5635 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.94 in 2025, whereas Return On Tangible Assets are likely to drop (1.44) in 2025. At this time, Immunitybio's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 254 M in 2025, whereas Total Current Assets are likely to drop slightly above 172.1 M in 2025.Immunitybio currently holds 726.72 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Geoffrey Barker | Viking Therapeutics | N/A | |
| Stephane Paquette | Krystal Biotech | N/A | |
| CPA CPA | Viking Therapeutics | 54 | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| Kathryn CPA | Krystal Biotech | 44 | |
| David Chien | Krystal Biotech | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Robert Yang | Elevation Oncology | N/A | |
| Lisa MD | Seres Therapeutics | 66 | |
| Ronald Plasterk | CureVac NV | N/A | |
| Adam Esq | BioLineRx | N/A | |
| Spencer JD | PDS Biotechnology Corp | 55 | |
| Wendy McDermott | Lexicon Pharmaceuticals | 54 | |
| Gregory Conn | PDS Biotechnology Corp | 70 | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Dixon Terry | Lexicon Pharmaceuticals | N/A | |
| Tom Garner | Lexicon Pharmaceuticals | N/A | |
| Joseph Reilly | Ardelyx | 52 | |
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
| Elizabeth Esq | Ardelyx | 61 | |
Management Performance
| Return On Asset | -0.56 |
Immunitybio Leadership Team
Elected by the shareholders, the Immunitybio's board of directors comprises two types of representatives: Immunitybio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunitybio. The board's role is to monitor Immunitybio's management team and ensure that shareholders' interests are well served. Immunitybio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunitybio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason JD, General Secretary | ||
| Sandeep MD, Chief Officer | ||
| Richard Adcock, CEO President | ||
| Helen Luu, Chief Officer | ||
| Leonard MD, Chief Officer | ||
| Jason Liljestrom, General Secretary | ||
| Barry MD, Chief Director | ||
| Hans MD, Chief Cellular | ||
| FRCS FACS, Executive Officer | ||
| Regan Lauer, Chief Officer | ||
| David Sachs, Principal CFO | ||
| RAC Dilon, Chief Officer | ||
| Sarah Singleton, Chief Advocacy |
Immunitybio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunitybio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.56 | ||||
| Operating Margin | (13.14) % | ||||
| Current Valuation | 3.46 B | ||||
| Shares Outstanding | 730.16 M | ||||
| Shares Owned By Insiders | 73.51 % | ||||
| Shares Owned By Institutions | 11.54 % | ||||
| Number Of Shares Shorted | 55.92 M | ||||
| Price To Sales | 362.49 X | ||||
| Revenue | 622 K | ||||
| Gross Profit | 7.33 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.